JP2023546504A5 - - Google Patents
Info
- Publication number
- JP2023546504A5 JP2023546504A5 JP2023525044A JP2023525044A JP2023546504A5 JP 2023546504 A5 JP2023546504 A5 JP 2023546504A5 JP 2023525044 A JP2023525044 A JP 2023525044A JP 2023525044 A JP2023525044 A JP 2023525044A JP 2023546504 A5 JP2023546504 A5 JP 2023546504A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- acid sequence
- chain variable
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063105804P | 2020-10-26 | 2020-10-26 | |
| US63/105,804 | 2020-10-26 | ||
| PCT/EP2021/079543 WO2022090158A1 (en) | 2020-10-26 | 2021-10-25 | Methods of reducing tau in human subjects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546504A JP2023546504A (ja) | 2023-11-02 |
| JP2023546504A5 true JP2023546504A5 (https=) | 2024-09-17 |
Family
ID=78402146
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023525044A Pending JP2023546504A (ja) | 2020-10-26 | 2021-10-25 | ヒト対象におけるタウを減少させる方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220127345A1 (https=) |
| EP (1) | EP4232155A1 (https=) |
| JP (1) | JP2023546504A (https=) |
| KR (1) | KR20230093499A (https=) |
| CN (1) | CN116916955A (https=) |
| AU (1) | AU2021367878A1 (https=) |
| CA (1) | CA3199806A1 (https=) |
| IL (1) | IL302386A (https=) |
| MX (1) | MX2023004831A (https=) |
| TW (1) | TW202233666A (https=) |
| WO (1) | WO2022090158A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3093200A1 (en) | 2018-03-05 | 2019-09-12 | Janssen Pharmaceutica Nv | Anti-phf-tau antibodies and uses thereof |
| JP7379764B1 (ja) | 2022-08-09 | 2023-11-15 | レール・リキード－ソシエテ・アノニム・プール・レテュード・エ・レクスプロワタシオン・デ・プロセデ・ジョルジュ・クロード | 空気分離装置および空気分離方法 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| BR112012013093A2 (pt) * | 2009-12-21 | 2017-12-12 | Genentech Inc | ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável |
| ITMI20120814A1 (it) * | 2012-05-11 | 2013-11-12 | Diego Dolcetta | Somministrazione intratecale, preferibilmente intraventricolare, di inibitori di mtor per la terapia di alcune malattie neurodegenerative, neuro-infiammatorie, neuro-oncologiche |
| US8980270B2 (en) * | 2013-01-18 | 2015-03-17 | Ipierian, Inc. | Methods of treating a tauopathy |
| MX2019006330A (es) * | 2016-12-07 | 2019-09-26 | Genentech Inc | Anticuerpos anti-tau y metodos de uso. |
| TWI771389B (zh) * | 2017-03-16 | 2022-07-21 | 美商健生生物科技公司 | 抗phf-tau抗體及其用途 |
| US10591492B2 (en) * | 2018-03-05 | 2020-03-17 | Janssen Pharmaceutica Nv | Assays to detect neurodegeneration |
| US20230075314A1 (en) * | 2019-04-29 | 2023-03-09 | Voyager Therapeutics, Inc. | VECTORIZED ANTIBODIES (vAb) AND USES THEREOF |
| WO2022090169A1 (en) * | 2020-10-26 | 2022-05-05 | Janssen Pharmaceutica Nv | Method of safe administration of anti-tau antibody |
-
2021
- 2021-10-25 CA CA3199806A patent/CA3199806A1/en active Pending
- 2021-10-25 WO PCT/EP2021/079543 patent/WO2022090158A1/en not_active Ceased
- 2021-10-25 CN CN202180087530.2A patent/CN116916955A/zh active Pending
- 2021-10-25 KR KR1020237017869A patent/KR20230093499A/ko active Pending
- 2021-10-25 EP EP21798703.1A patent/EP4232155A1/en active Pending
- 2021-10-25 AU AU2021367878A patent/AU2021367878A1/en active Pending
- 2021-10-25 MX MX2023004831A patent/MX2023004831A/es unknown
- 2021-10-25 JP JP2023525044A patent/JP2023546504A/ja active Pending
- 2021-10-25 IL IL302386A patent/IL302386A/en unknown
- 2021-10-25 US US17/509,889 patent/US20220127345A1/en active Pending
- 2021-10-25 TW TW110139444A patent/TW202233666A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023517236A5 (https=) | ||
| US11591406B2 (en) | Treatment for multiple myeloma (MM) | |
| JP2025183307A5 (https=) | ||
| JP2021525806A5 (https=) | ||
| JP2024534602A5 (https=) | ||
| JP2023520771A5 (https=) | ||
| JP2023548064A5 (https=) | ||
| JP2019532970A5 (https=) | ||
| JP2024540226A5 (https=) | ||
| JP2024516698A5 (https=) | ||
| JP2023546504A5 (https=) | ||
| JP2023546503A5 (https=) | ||
| CA3199808A1 (en) | Method of safe administration of anti-tau antibody | |
| AU2023375340A1 (en) | Methods for the treatment of cardiovascular disease | |
| JP2024540435A5 (https=) | ||
| JP2023506779A5 (https=) | ||
| JP2022521773A5 (https=) | ||
| US20220213223A1 (en) | Treatment of Al Amyloidosis with the Combination of Monoclonal Antibodies Agains Immunoglobulin Light Chains and the CD38 Cell Membrane Molecule on Antibody-Producing And Other Immune Cells | |
| JP2022549218A5 (https=) | ||
| JP2025537529A (ja) | リヒター症候群を治療するためのｃｄ３およびｃｄ２０に対する二重特異性抗体 | |
| US20140228316A1 (en) | PPS for the prevention of potential adverse effects caused by CD3 specific binding domains | |
| JP2025504383A5 (https=) | ||
| JP2020517648A5 (https=) | ||
| WO2026060205A1 (en) | PAN-ELR+ CXC CHEMOKINE ANTIBODIES AND IL-23p19 ANTIBODIES FOR THE TREATMENT OF ULCERATIVE COLITIS | |
| JP2025084861A (ja) | 再発型の多発性硬化症を治療するための方法 |